Evidence map›Paper›PMID 34997006›Full record

ArticleScientific reports2022

Comparative proteomic analysis of nuclear and cytoplasmic compartments in human cardiac progenitor cells.

Guillermo Albericio, Susana Aguilar, Jose Luis Torán, Rosa Yañez, Juan Antonio López, Jesús Vázquez, Carmen Mora, Antonio Bernad

Open access · goldAbstract readComparative Study
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Guillermo Albericio *Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB-CSIC), C/ Darwin 3, Campus Universidad Autónoma de Madrid, 28049, Madrid, Spain.
Susana Aguilar *Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB-CSIC), C/ Darwin 3, Campus Universidad Autónoma de Madrid, 28049, Madrid, Spain.
Jose Luis ToránDepartment of Immunology and Oncology, Centro Nacional de Biotecnología (CNB-CSIC), C/ Darwin 3, Campus Universidad Autónoma de Madrid, 28049, Madrid, Spain.
Rosa YañezHematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain.
Juan Antonio LópezLaboratory of Cardiovascular Proteomics, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029, Madrid, Spain.
Jesús VázquezLaboratory of Cardiovascular Proteomics, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029, Madrid, Spain.
Carmen MoraDepartment of Immunology and Oncology, Centro Nacional de Biotecnología (CNB-CSIC), C/ Darwin 3, Campus Universidad Autónoma de Madrid, 28049, Madrid, Spain.
Antonio BernadDepartment of Immunology and Oncology, Centro Nacional de Biotecnología (CNB-CSIC), C/ Darwin 3, Campus Universidad Autónoma de Madrid, 28049, Madrid, Spain. abernad@cnb.csic.es.
Universidad Autónoma de Madrid · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ESCentro de Investigaciones Energéticas, Medioambientales y Tecnológicas · ESCentro Nacional de Biotecnología · ESSpanish National Centre for Cardiovascular Research · ESUniversidad Complutense de Madrid · ES

Funding

European Union HEALTH-2009_242038Research Program of the Comunidad Autónoma de Madrid S2017/BMD-3692Spanish Ministry of Science and Innovation SAF2015-70882-R
6 · The paper itself

Abstract

Clinical trials evaluating cardiac progenitor cells (CPC) demonstrated feasibility and safety, but no clear functional benefits. Therefore a deeper understanding of CPC biology is warranted to inform strategies capable to enhance their therapeutic potential. Here we have defined, using a label-free proteomic approach, the differential cytoplasmic and nuclear compartments of human CPC (hCPC). Global analysis of cytoplasmic repertoire in hCPC suggested an important hypoxia response capacity and active collagen metabolism. In addition, comparative analysis of the nuclear protein compartment identified a significant regulation of a small number of proteins in hCPC versus human mesenchymal stem cells (hMSC). Two proteins significantly upregulated in the hCPC nuclear compartment, IL1A and IMP3, showed also a parallel increase in mRNA expression in hCPC versus hMSC, and were studied further. IL1A, subjected to an important post-transcriptional regulation, was demonstrated to act as a dual-function cytokine with a plausible role in apoptosis regulation. The knockdown of the mRNA binding protein (IMP3) did not negatively impact hCPC viability, but reduced their proliferation and migration capacity. Analysis of a panel of putative candidate genes identified HMGA2 and PTPRF as IMP3 targets in hCPC. Therefore, they are potentially involved in hCPC proliferation/migration regulation.

Indexed as

ProteomeProteomicsCell MovementCell NucleusCell ProliferationCells, CulturedCytoplasmFibroblastsGene Expression RegulationHMGA2 ProteinHumansInterleukin-1alphaMesenchymal Stem CellsMyocytes, CardiacOxidative StressReceptor-Like Protein Tyrosine Phosphatases, Class 2HMGA2 ProteinHMGA2 protein, humanIGF2BP3 protein, humanIL1A protein, humanInterleukin-1alphaProteomePTPRF protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 2RNA-Binding Proteins

Identifiers

PMID34997006
PMCPMC8742012
OpenAlexW4206531785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.